Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis

Affiliations

¹ University Hospital of Münster, Münster, Germany.
² Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China.
³ Ghent University, Ghent, Belgium.
⁴ University of Dundee, Dundee, UK.
⁵ Rochester Regional Health, Rochester, New York, USA.
⁶ Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
⁷ Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Catalonia, Spain.
⁸ Sanofi, Bridgewater, New Jersey, USA.
⁹ Regeneron Pharmaceuticals, Tarrytown, New York, USA.
¹⁰ Sanofi, Gentilly, France.
¹¹ Sanofi, Chilly-Mazarin, France.
¹² Sanofi, Reading, UK.

Claus Bachert et al. Allergy. 2024 Oct.

. 2024 Oct;79(10):2858-2861.

doi: 10.1111/all.16189. Epub 2024 Jun 8.

¹ University Hospital of Münster, Münster, Germany.
² Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China.
³ Ghent University, Ghent, Belgium.
⁴ University of Dundee, Dundee, UK.
⁵ Rochester Regional Health, Rochester, New York, USA.
⁶ Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
⁷ Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Catalonia, Spain.
⁸ Sanofi, Bridgewater, New Jersey, USA.
⁹ Regeneron Pharmaceuticals, Tarrytown, New York, USA.
¹⁰ Sanofi, Gentilly, France.
¹¹ Sanofi, Chilly-Mazarin, France.
¹² Sanofi, Reading, UK.

No abstract available

References

1. Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812‐2820.e3. doi:10.1016/j.jaip.2019.05.009 PMID: 31128376.
1. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449‐1456.e4. doi:10.1016/j.jaci.2015.12.1324 PMID: 26949058.
1. Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C. Serum periostin, IgE, and SE‐IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;140(6):1705‐1708.e3. doi:10.1016/j.jaci.2017.07.031 PMID: 28870464.
1. Bachert C, Laidlaw TM, Cho SH, et al. Effect of Dupilumab on type 2 biomarkers in chronic Rhinosinusitis with nasal polyps: SINUS‐52 study results. Ann Otol Rhinol Laryngol. 2023;132:1649‐1661. doi:10.1177/00034894231176334. PMID: 37322842.
1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet. 2019;394(10209):1638‐1650. doi:10.1016/S0140-6736(19)31881-1 PMID: 31543428.